Know Cancer

forgot password

Phase I/II Study of Reirradiation of Recurrent or Progressive Brainstem Glioma

Phase 1/Phase 2
17 Years
Open (Enrolling)
Brain Cancer

Thank you

Trial Information

Phase I/II Study of Reirradiation of Recurrent or Progressive Brainstem Glioma

Radiation Therapy Administration:

If you are found to be eligible to take part in this study, you will be assigned to a dose
level of radiation therapy based on when you join this study. Three (3) dose levels of
radiation therapy will be tested. Three (3) participants will be enrolled at each dose
level. The first group of participants will receive the lowest dose level. Each new group
will be randomly assigned (as in the roll of dice) to one of the dose levels, and the
assignment will also depend on how the previous participants have done. Participants will
not be assigned to one of the higher 2 of the 3 dose levels unless the lower dose level is
found to be tolerable. The first and second groups will receive 12 treatments and the third
group will receive 14 treatments (Monday through Friday for about 2½ weeks). Your doctor
will tell you how many treatments you will receive.

You may be given drugs to help prevent side effects. The study staff will tell you about
these drugs, how they will be given, and the possible risks.

Study Visits:

About 2-4 days before you start radiation therapy, you will have a simulation. During the
simulation session, a mask will be made of your face and head to keep you still. You will
also have a computed tomography (CT) scan. This process allows the radiation planning to
take place. Sedation by an anesthesiologist (anesthesia doctor) will be used if needed for
young children to allow the radiotherapy to be delivered safely.

One (1) time a week for 3 weeks, and then 1 time a month (30 days +/- 10 days) for 2 months
or unless the disease gets worse:

- Any updates to your medical history will be recorded.

- You will have a physical exam, including a neurological exam.

- Your performance status will be recorded.

- You will fill out the quality-of-life questionnaire.

- You will be asked about any side effects you may have had.

You will have a magnetic resonance imaging (MRI) scan of the brain within 1 month after
joining the study.

Length of Treatment:

You may continue receiving radiation therapy for 12 or 14 treatments. You will no longer be
able to receive radiation therapy if the disease gets worse, if intolerable side effects
occur, or if you are unable to follow study directions.

Follow-up Visits:

One (1) month after you finish radiation therapy, at 6-8 weeks, then every 2-3 months after
that from then on, you will have an MRI scan to check the status of the disease. The MRI
scan will include advanced imaging to learn if the tumor has come back or if there is brain
tissue damage from the radiation. With this type of imaging, a temporary infusion line with
a bigger than standard size needle will be inserted to your vein if you do not already have
a power port-a-cath in place. This may take between 20-30 minutes.

This is an investigational study. Radiation therapy in this study is delivered using
FDA-approved and commercially available methods. It is investigational to find the best
dose of radiation therapy to use for repeat radiation therapy.

Up to 30 patients will take part in this study. All will be enrolled at MD Anderson.

Inclusion Criteria:

1. Diagnosis of diffuse intrinsic pontine glioma (DIPG) by magnetic resonance (MRI)
imaging defined as tumor that has a pontine epicenter and is diffuse (tumor that
involves the majority (>50%) of the brainstem) on T2 or Fluid attenuation inversion
recovery (FLAIR) imaging rather than focal. Histologic confirmation is not required

2. Radiation therapy to brain for Diffuse Intrinsic Pontine Glioma (DIPG) that was
completed at least 10 months prior to planned reirradiation

3. Clinical progression of symptoms with any radiographic progression on MRI within 21
days prior to registration (any progression in size or enhancement on MRI along with
worsening symptoms, will be defined as progression prior to enrollment). Radiographic
progression is defined as any increase in tumor size (in axial or sagittal images) or
progressive contrast enhancement and abnormal T2/FLAIR signal by MRI.

4. Signed informed consent by patient and/or parents or legal guardian

5. Lansky/Karnofsky Performance Status score of 40-100

6. Central nervous system function defined as not severely somnolent or comatose
(central cortical neurotoxicity scale
7. Life expectancy of >/= 8 weeks

Exclusion Criteria:

1. Prior radiation of greater than 60 Gy to >20% of brainstem.

2. Patients with Neurofibromatosis 1 because the biologic behavior of their tumors may
be more benign

3. Asymptomatic patients because the primary goal of treatment is palliation of symptoms

4. Pregnancy

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Optimal Dose Level Among Three Radiation Therapy (RT) Dose Levels

Outcome Description:

Optimal dose level among three RT dose levels, defined in terms of the biologically equivalent dose (BED). The BED is given by the formula BED = (Total Dose)*(1 + d/3), denoting d = dose/fraction, with the constant 3 corresponding to brain tissue.

Outcome Time Frame:

1 month after radiation therapy

Safety Issue:


Principal Investigator

Anita Mahajan, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

UT MD Anderson Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

December 2011

Completion Date:

Related Keywords:

  • Brain Cancer
  • Brain cancer
  • Recurrent or progressive brainstem glioma
  • Diffuse Intrinsic Pontine Glioma
  • DIPG
  • Reirradiation
  • ReRT
  • Photon radiation therapy
  • XRT
  • Brain Neoplasms
  • Glioma
  • Pontine Glioma



UT MD Anderson Cancer CenterHouston, Texas  77030